Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Drug entities : Biogen inc. save search
Pancreatitis Disease Market Insights: Epidemiology Study, Drug Development, Clinical Trial and Price Reimbursement | Disease Landscape Insights
Published: 2023-10-12 (Crawled : 17:00) - prnewswire.com
IDXX | $476.29 -0.31% -0.31% 570K
|
Health Technology
|
| O: 0.31%
H: 0.0%
C: -4.24%
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: 0.15%
H: 0.41%
C: -2.22%
drug disease trial market
Redefining Hepatitis B Disease Management with DLI's drug insights, pipeline assessment, and clinical trial management endeavours| Disease Landscape Insights
Published: 2023-10-10 (Crawled : 08:00) - prnewswire.com
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: 0.1%
H: 0.27%
C: -0.13%
hepatitis management drug disease pipeline trial
Gene Therapy Market size is set to grow by USD 4,613.9 million from 2022 to 2027; Increase in special drug designations boosts the market growth - Technavio
Published: 2023-06-12 (Crawled : 15:00) - prnewswire.com
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: -0.68%
H: 3.23%
C: 1.55%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.16%
H: 0.11%
C: -0.76%
ORTX | $16.7 0.0% 370K
|
Health Technology
|
| O: 0.62%
H: 4.57%
C: 2.04%
GBIO | $2.81 1.08% 1.07% 250K
|
Health Technology
|
| O: 0.0%
H: 11.57%
C: 6.4%
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: 3.52%
H: 0.0%
C: -1.99%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.22%
H: 0.0%
C: -0.86%
ADAP | $0.97 7.97% 7.38% 1.5M
|
Health Technology
|
| O: -0.75%
H: 7.14%
C: 6.12%
ABEO | $7.6 0.93% 0.92% 390K
|
Health Technology
|
| O: 0.0%
H: 4.4%
C: 3.29%
drug set therapy growth market
AI Proteins Announces the Formation of a Scientific Advisory Board Made up of Experts in Biotech and FDA Drug Approval
Published: 2023-05-31 (Crawled : 17:00) - biospace.com/
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: 0.0%
H: 0.3%
C: -0.76%
fda drug biotech approval
Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer’s Disease
Published: 2023-05-15 (Crawled : 23:00) - globenewswire.com
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: -0.41%
H: 0.01%
C: -0.96%
drug disease health alzheimer’s treatment lecanemab canada submission
Gene therapy market size to grow by USD 4,613.9 million from 2022 to 2027; The increase in special drug designations to drive growth- Technavio
Published: 2023-03-16 (Crawled : 02:00) - prnewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 1.16%
H: 0.73%
C: 0.73%
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: 0.44%
H: 0.29%
C: 0.29%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.18%
H: 0.77%
C: 0.64%
ORTX | $16.7 0.0% 370K
|
Health Technology
|
| O: -4.62%
H: 4.44%
C: -6.05%
GBIO | $2.81 1.08% 1.07% 250K
|
Health Technology
|
| O: -0.55%
H: 6.69%
C: 1.95%
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: -1.11%
H: 2.97%
C: 2.23%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.49%
H: 0.39%
C: 0.36%
ADAP | $0.97 7.97% 7.38% 1.5M
|
Health Technology
|
| O: -2.65%
H: 14.55%
C: 9.09%
ABEO | $7.6 0.93% 0.92% 390K
|
Health Technology
|
| O: -2.29%
H: 3.52%
C: -0.78%
drug therapy market
Sage Therapeutics and Biogen Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
Published: 2023-02-06 (Crawled : 12:20) - biospace.com/
SAGE | $13.35 2.42% 2.36% 1.3M
|
Health Technology
|
| O: 0.27%
H: 6.75%
C: 3.25%
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: 0.51%
H: 2.52%
C: 1.12%
treatment fda drug application grants therapeutics review depression major depressive disorder
Biogen and Sage Therapeutics Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
Published: 2023-02-06 (Crawled : 12:00) - globenewswire.com
SAGE | $13.35 2.42% 2.36% 1.3M
|
Health Technology
|
| O: 0.27%
H: 6.75%
C: 3.25%
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: 0.51%
H: 2.52%
C: 1.12%
treatment fda drug application grants therapeutics review depression major depressive disorder
Sage Therapeutics and Biogen Complete Rolling Submission of New Drug Application for Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
Published: 2022-12-06 (Crawled : 13:20) - biospace.com/
SAGE | $13.35 2.42% 2.36% 1.3M
|
Health Technology
|
| O: -0.25%
H: 0.44%
C: -4.15%
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: -0.18%
H: 0.97%
C: -0.26%
treatment drug application therapeutics depression submission major depressive disorder
Biogen Announces FDA’s 3-Month Extension of Review Period for the New Drug Application for Tofersen
Published: 2022-10-17 (Crawled : 12:00) - globenewswire.com
IONS | $40.64 -0.42% -0.42% 850K
|
Health Technology
|
| O: 0.97%
H: 1.62%
C: -0.62%
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: 0.54%
H: 2.99%
C: 1.32%
drug extension application review
Feinstein Institutes-Led Lupus Phase 2 Clinical Trial Shows Promise of an Investigational Drug
Published: 2022-09-16 (Crawled : 16:00) - biospace.com/
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: -0.09%
H: 1.28%
C: 0.83%
drug lupus trial promise phase 2
New Therapeutics Options in Rheumatoid Arthritis Pipeline as 120+ Key Companies are Working on Drug Profiles | DelveInsight
Published: 2022-07-26 (Crawled : 16:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.17%
H: 0.48%
C: 0.17%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.1%
H: 0.0%
C: 0.0%
IMAB | $1.81 0.56% 0.55% 340K
|
Health Technology
|
| O: -0.28%
H: 0.0%
C: -1.61%
GLPG | News | $29.095 0.64% 0.64% 87K
|
Health Technology
|
| O: -1.81%
H: 2.67%
C: 2.16%
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: -0.42%
H: 3.54%
C: 2.01%
drug companies therapeutics
FDA Accepts Biogen’s New Drug Application and Grants Priority Review of Tofersen for a Rare, Genetic Form of ALS
Published: 2022-07-26 (Crawled : 12:00) - globenewswire.com
IONS | $40.64 -0.42% -0.42% 850K
|
Health Technology
|
| O: 1.96%
H: 0.2%
C: -2.61%
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: -0.42%
H: 3.54%
C: 2.01%
fda drug genetic als application grants review
Kallyope, Pioneers in Drug Discovery via the Gut-Brain Axis, Advances Discovery and Development Teams With New Appointments
Published: 2022-07-06 (Crawled : 12:20) - biospace.com/
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: 1.98%
H: 1.73%
C: 1.35%
drug train
Dementia and Movement Disorder Treatment Market: 45% of Growth to Originate from North America | By Drug Class and Geography - Forecast and Analysis 2022-2026
Published: 2022-05-11 (Crawled : 01:00) - prnewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 0.81%
H: 0.0%
C: -0.09%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.27%
H: 1.2%
C: -0.85%
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: -0.65%
H: 1.14%
C: -1.14%
BHC | $8.69 1.05% 0.0% 2.9M
|
Health Technology
|
| O: 15.69%
H: 13.62%
C: 9.04%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.21%
H: 0.0%
C: 0.0%
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: -0.15%
H: 3.04%
C: -0.63%
america treatment dementia drug growth
Sage Therapeutics and Biogen Initiate Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration for Zuranolone for the Potential Treatment of Major Depressive Disorder (MDD)
Published: 2022-05-02 (Crawled : 11:00) - biospace.com/
SAGE | $13.35 2.42% 2.36% 1.3M
|
Health Technology
|
| O: -1.12%
H: 0.0%
C: 0.0%
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: -1.95%
H: 1.37%
C: 0.49%
treatment drug application therapeutics food potential submission major depressive disorder
Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis
Published: 2022-03-28 (Crawled : 12:20) - biospace.com/
IONS | $40.64 -0.42% -0.42% 850K
|
Health Technology
|
| O: -1.12%
H: 1.96%
C: -1.05%
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: -0.42%
H: 1.04%
C: 0.76%
drug results topline sclerosis phase 1
Central Nervous System (CNS) Stimulant Drugs Market to grow at a CAGR of 5.74 by 2026 | Rise in CNS Disorders to Boost Growth | 17000+ Technavio Reports
Published: 2022-03-14 (Crawled : 16:00) - prnewswire.com
ALPMF | $9.17 43.47% 16K
|
Health Technology
|
| O: 0.7%
H: 0.0%
C: 0.0%
GLAXF | News | $20.2 -14.18% 510
|
Health Technology
|
| O: 9.61%
H: 0.0%
C: -0.57%
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -2.53%
H: 0.0%
C: -0.08%
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: -3.28%
H: 0.0%
C: 0.0%
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: 2.42%
H: 0.31%
C: -0.47%
KMPH | $5.46 6.04% 0
|
Manufacturing
|
| O: 0.0%
H: 1.34%
C: -4.4%
VTRS A | $11.25 1.17% 1.16% 4.7M
|
Health Technology
|
| O: 1.4%
H: 1.08%
C: -3.44%
TMO | News | $544.78 0.6% 0.0% 1.7M
|
Health Technology
|
| O: -1.31%
H: 0.0%
C: 0.0%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.54%
H: 0.0%
C: 0.0%
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: 0.42%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -3.24%
H: 0.0%
C: 0.0%
JAZZ | $109.96 0.63% 0.63% 760K
|
Health Technology
|
| O: 0.1%
H: 1.14%
C: -0.59%
ENDP | $0.2926 -9.6%
|
Health Technology
|
| O: -1.72%
H: 3.51%
C: -5.26%
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: 0.47%
H: 1.48%
C: -2.43%
order drug system nervous system report growth
Psychedelic Drugs Market Growing as Prevalence of Mental Health Issues are Increasing Globally
Published: 2022-02-24 (Crawled : 14:00) - prnewswire.com
KTTA | $7.15 -1.19% 540
|
|
| O: -8.82%
H: 7.53%
C: 4.3%
TEVA | $12.86 0.63% 0.0% 10M
|
Health Technology
|
| O: -3.87%
H: 3.38%
C: 2.99%
RLMD | $4.0 -6.98% -7.5% 150K
|
Health Technology
|
| O: -3.79%
H: 9.54%
C: 9.06%
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: -2.02%
H: 1.07%
C: -0.85%
ATRA | $0.6755 -2.34% -2.4% 1.6M
|
Health Technology
|
| O: -5.17%
H: 9.75%
C: 9.26%
health drug growing
Japan’s First Committee on New Drugs of The Pharmaceutical Affairs and Food Sanitation Council Seeks Additional Data; Aducanumab Remains under Review
Published: 2021-12-22 (Crawled : 12:30) - globenewswire.com
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: 0.69%
H: 0.09%
C: -0.75%
new drug ema air drug food under review
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.